Trial Profile
Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Inflammatory bowel diseases
- Focus Pharmacokinetics
- Sponsors Holy Stone Healthcare
- 21 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 18 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 18 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.